Ultragenyx Faces Securities Fraud Suit Over Setrusumab Study Misrepresentation
Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.
RAREsecurities fraudclass action lawsuit